New Zealand menopause hormone therapy demand rises as training gaps persist

More New Zealand women are asking for menopause hormone therapy, but the health system is struggling to meet them at the bedside and in the classroom. Rising awareness of treatment benefits has pushed demand high enough that manufacturers could not keep up, and Pharmac has temporarily rationed some medicines while doctors navigate a field that has changed far more quickly than much of medical training.

The most immediate pressure has been on access. RNZ reported on April 30, 2026, that progesterone capsules would be dispensed monthly instead of three-monthly because of ongoing supply issues. Pharmac has also said a global shortage was still affecting Estradot patches, even as Estradiol TDP Mylan and Estradot remained the funded patch brands from December 1, 2025. For patients trying to manage hot flushes and night sweats, those shortages turn a routine prescription into an extra barrier.

The deeper problem is confidence. Many doctors were trained before current menopause evidence settled into today’s practice, and some did not receive up-to-date menopause education at all. That matters because clinical care has shifted since the late 1990s, when hormone therapy was often offered broadly in specialist training. Today, most women prescribed treatment receive body-identical hormones, including transdermal estradiol patches or gel and progesterone capsules, and the decision is meant to be tailored rather than automatic.

The evidence base is also different from the one that shaped decades of fear. Recent research has shown little to no association between menopausal hormone therapy and stroke or blood clots, while also showing benefits for bone health. The U.S. Food and Drug Administration announced in November 2025 that it would remove broad black box warnings from menopause hormone therapy products, a sign that regulators are recalibrating after more than two decades of caution. The Menopause Society and NICE guidelines now say systemic hormone therapy generally outweighs the risks for many women younger than 60 or within 10 years of menopause onset, as long as there are no contraindications.

Even so, uptake remains uneven. AARP research published in 2024 found that only 15 percent of women surveyed had tried hormone therapy for menopause symptoms, while nearly half used supplements instead. In New Zealand, Michelle Wise of the University of Auckland has been central to the discussion of why better evidence has not yet translated into better care. The bottleneck is no longer just demand. It is training, access and stigma, all landing on midlife patients who still have to fight for evidence-based treatment.